Prolactin (PRL), interacting with other hormones from the pituitary, gonad, and placenta, activates speci®c signals that drive the appropriately timed morphological and functional development of the mammary gland. A mouse model of isolated PRL de®ciency (PRL 7/7 ) was created by gene disruption in an eort to further understand the molecular basis of mammary gland development and breast cancer. Whereas primary ductal growth was normal in PRL 7/7 mice, ductal arborization was minimal (branches/mm 2 =1.5+0.5), and lobular budding was absent. Replacement therapy with PRL injections stimulated a modest degree of lobular budding and ductal arborization (3.75+0.9). Pituitary transplants to the kidney capsule of PRL 7/7 mice restored lobular budding and ductal arborization, to the full extent of that seen in control animals (20.3+5.5). Pregnancy, established by mating progesterone-treated PRL 7/7 females with PRL 7/7 males, led to complete morphological development of the mammary gland, appropriate to the gestational stage. PRL treatment stimulated tyrosine phosphorylation and DNA binding activity of Stat5a, but not Stat1 in PRL 7/7 or PRL +/7 females, and Stat5a, but not Stat1, was elevated by estradiol within 24 h. PRL-de®cient mice were crossed with mice expressing a dominant oncogene (polyoma middle-T antigen driven by the MMTV promoter, PyVT mice). Palpable (1 mm 3 ) tumors were detected an average of 9 days earlier in hormonally normal females (PRL +/7 :PyVT) compared with littermates that were PRL-de®cient (PRL Introduction PRL has a well established role in promoting milk protein synthesis during lactation, and is understood to provide an important developmental signal during mammary epithelial growth (Lyons et al., 1958) . We produced mice with a disruption of the PRL gene with the ultimate goal of gaining a better understanding of both normal mammary gland development and breast tumorigenesis (Horseman et al., 1997) . Here we show additional details to characterize the control of mammary gland development in this mouse model, and compare the growth of oncogene-induced mammary tumors in normal and PRL gene-disrupted mice.
Although a great deal is known about PRL eects on milk protein synthesis and intracellular signal transduction, neither the precise morphogenetic steps that are driven by PRL, nor the genes responsible for PRL-induced mammary morphogenesis are yet known. Experimental analysis of PRL actions in mouse mammary glands has been, of necessity, limited to studying either tissues from midpregnant animals or cells in culture that have been previously exposed to lactogens, and then withdrawn from hormonal stimulation. The mouse PRL gene was disrupted by homologous recombination (Horseman et al., 1997) , and these animals provided an in vivo system in which pubertal mammary organogenesis proceeds in the absence of PRL from either pituitary or from extrapituitary sources. The arrested mammary gland development in PRL gene-disrupted mice is an experimental platform from which to study PRL-regulated events at their earliest stages.
PRL has been implicated as a tumor promoter in rodent mammary glands (Welsch and Nagasawa, 1977) , but its potential contribution to human breast cancer has been obscure and controversial. The synthesis of substantial amounts of extrapituitary PRL in human breast, as well as other tissues (Clevenger et al., 1995) , and the redundant pathways by which PRL might contribute to breast tumorigenesis demand that experiments be directed toward gaining a better understanding of PRL actions on breast cancer. Herein we report details of mammary gland morphogenesis in PRL gene-disrupted mice that have been exposed to hormones, pituitary transplants and pregnancy. We show that Stat5a, but not Stat1, is activated following PRL exposure in the mammary glands of PRL gene-disrupted mice. PRL gene-disrupted mice were mated to transgenic mice that overexpress the polyoma middle T antigen, and the growth of breast tumors was signi®cantly slower in comparison with PRL-expressing littermates. These results, for the ®rst time, point to PRL as a modulator of oncogene-induced breast tumor growth.
Results

Development of mammary glands in PRL
7/7 mice Photomicrographs of mammary gland whole mounts in Figure 1 compare the eects of chronic exposure to PRL and progesterone on mammary gland develop-
mice. The development of the mammary glands in nulliparous mice includes three morphologically distinguishable features: (1) elongation and dichotomous branching of the primary ducts, extending to the boundaries of the mammary fat pad; (2) subordinate arborization of the ducts to produce a highly branched network; and, (3) alveolar budding. The mature gland in the non-pregnant, non-lactating female mouse consists of a ®nely branched ductal network with multiple alveolar buds associated with each subordinate branch. In some inbred strains of mice the mammary gland does not fully mature until the ®rst pregnancy. In others, including the mixed Swiss Black/129Sv background used in these studies, the gland matures in the nulliparous mouse under the in¯uence of hormones during the estrous cycles. As reported by us previously (Horseman et al., 1997) , extensive subordinate arborization and alveolar budding were observed in the glands of heterozygous (PRL +/7 ) mice (Figure 1a) . Ductal development was arrested in the mammary glands of PRL 7/7 mice, such that the gland consisted of a network of dichotomous branches with no subordinate branching or alveolar budding. Engraftment of two normal (PRL +/7 ) pituitary glands to the kidney capsule of PRL 7/7 mice resulted in extensive development of the mammary glands by 18 days after the graft (Figure 1c ). Glands from pituitary-grafted mice consisted of ductal networks that included extensive subordinate branching and alveolar budding. A sustained progesterone stimulus, via an implanted progesterone pellet, resulted in an obvious increase in the number of subordinate branches, but there were no alveolar buds associated with these branches (Figure 1d ). The mean branch density (per mm 2 ) was signi®cantly dierent among the groups (F s =9.45; df 3, 7; P50.02) by analysis of variance. Branch density was intermediate in the progesterone-treated PRL 7/7 mice (mean 9.8, range 7 ± 13, n=3) between normal PRL +/7 controls (mean 19.6, range 15 ± 25, n=3) and untreated PRL 7/7 controls (mean 3.3, range 2 ± 4, n=3). The mean branch density in the pituitary-engrafted PRL 7/7 mice was 15.8 (range 11 ± 20, n=2), approaching that of the normal PRL +/7 controls. Progesterone-implanted females were made pregnant by mating with PRL 7/7 males, and the mammary glands of these PRL-de®cient mice underwent extensive development of the lobuloalveolar system by day 18 post coitus ( Figure 2a ). In aged (17 month old) PRL 7/7 mice the mammary gland development was very limited (Figure 2b ). The gland consisted of poorly developed dichotomous branches with no subordinate branching ) control mature adult mammary gland, the mammary lymph node is labeled with an arrow, and serves as a reference point in each of the panels, black bar=2 mm; (b) Adult PRL 7/7 control mammary gland; (c) Adult PRL 7/7 mouse mammary gland, stimulated with engrafted pituitary tissue; (d) Adult PRL 7/7 mouse mammary gland, stimulated with implanted progesterone pellet or alveolar budding. Treatment of prepubertally ovariectomized PRL 7/7 mice with estradiol benzoate injections (four injections during 12 days) induced hypertrophy of the terminal end buds (Figure 2c ). There were variable amounts of growth and dichotomous branching in the primary ductal system in the mice treated with estradiol, but no evidence of the delicate subordinate branching pattern, or of the alveolar buds that decorate the ducts of the PRLexposed glands. Injections of estradiol plus progesterone (methyl-OH progesterone acetate), and PRL ( Figure 2d ) in ovariectomized mice induced extensive ductal branching and a modest degree of alveolar budding. The most mature portion of the gland treated with estradiol, progesterone, and PRL is highlighted in Figure 2d . This region included numerous subordinate branches and alveolar buds, which indicate progression toward a more highly dierentiated state under the combined in¯uences of the hormone treatments. These data allow us to conclude that the mammary gland can be regulated normally by hormone replacements in mice that carry a targeted mutation of the PRL gene.
PRL stimulates Stat5 DNA binding and tyrosine phosphorylation in PRL-deficient mice
To determine whether signal transduction in the mammary gland of PRL-de®cient mice was similar to that of their normal siblings, we analysed the induction of Stat protein DNA binding and tyrosine phosphorylation. The rat b-casein PRL-response element (PRE) was radiolabeled, incubated with mammary gland protein extracts and subjected to native polyacrylamide gel electrophoresis. Thirty minutes after PRL treatment there was an equivalent activation of PRE-binding in extracts from either PRL 7/7 or PRL +/7 mice ( Figure  3a ). The PRL-induced binding to the PRE was supershifted with anti-Stat5a, but anti-Stat1 had no eect on the PRL-induced activity. Western blotting showed that Stat5a levels and PRL-induced Stat5 tyrosine phosphorylation were similar in PRL 7/7 and normal control mice ( Figure 3b ).
PRL deficiency slows the growth of oncogene-induced breast tumors
The hypothesis that PRL modulates oncogene-induced breast tumor growth was tested in mice expressing the polyoma virus middle T antigen (PyVT) under the control of the mouse mammary tumor virus (MMTV) promoter, which develop multifocal breast tumors in nulliparous females (Guy et al., 1992) . The strategy for testing our hypothesis was to mate transgenic PyVT :PRL +/7 females. This approach was chosen because females carrying the MMTV-PyVT transgene develop tumors at a very young age. They are poor mothers because of lactational insuciency and the rapid progress of the tumors. Because PRL 7/7 males are fertile, the transgene could be carried in the male, where tumors develop later. Mice were examined twice weekly beginning after they reached 5 weeks of age, by a ) that was treated with injections of estradiol, progesterone, and PRL. Note that pregnancy leads to extensive mammary gland development, even in the absence of PRL, and that mammary gland development in the nulliparous mice remains very sparse even into old age in the absence of PRL. The area outlined in (d) indicates the area nearest the nipple, which has reached a stage of dense ductal development under the in¯uences of the hormone injections `blinded' technician, and the earliest tumors were detectable by palpation (1 mm diameter) at about 45 days of age. The size of tumors was recorded after each examination. The ages at which the technician ®rst detected tumors, and 1 cm tumors, were analysed by analysis of variance (Figure 4a ). In control mice the average age at which palpable tumors were ®rst detected was 51.7 (+2.0, n=11) days. Tumors were palpated 9 days later, on average, in PRL 7/7 mice (60.7+2.7 days, n=7, P50.02). Tumor growth was monitored until the largest tumor in each mouse had reached a diameter of 1 cm. In PRL 7/7 mice 1 cm tumors were observed on day 81.2+5.5, compared with PR +/7 mice, in which tumors reached 1 cm diameter by day 69.5+2.6 (P50.05). The dierence in tumor growth rate between the genotypes was calculated from the divergence of the growth curves to be about 30% (D11.8 days/D9 days=131%). Similarly, if one assumes that the active growth of the tumors begins early during puberty, coinciding with the initiation of pubertal mammary gland growth at about day 35, the growth rate was 32% faster in normal PRL +/7 mice (2.9 mm/day) than that in PRL 7/7 mice (2.2 mm/day). While these values do not take into account variables such as total tumor burden, they point to the enhanced trophic support of tumor growth in the PRL +/7 genotype. The level of PyVT expression was similar by Northern analysis of control and PRL 7/7 mice. Tumors were observed histologically to be adenocarcinomas that were indistinguishable on a pathological basis in the PRL 7/7 and PRL +/7 mice (Figure 4b ).
Discussion
The prolactin (PRL) system has evolved in mammals to perform a special role in controlling mammary gland development and lactation (Nicoll, 1974) . These PRL actions, along with possible activities in breast cancer (Ginsburg and Vonderhaar, 1995) , provided an impetus to develop PRL gene-disrupted mice (Horseman et al., 1997) . In this paper we have used several approaches to investigate PRL actions in mammary gland development and breast cancer. Morphological changes in the mammary glands were analysed by qualitative assessments using well de®ned criteria for dichotomous branching, subordinate branching and alveolar budding. Objective quanti®ca-tion of ductal branch density was used to allow for statistical comparisons of epithelial development. We had previously shown that the mammary epithelium in PRL-de®cient mice was limited to a system of simple branched ducts. Normal (PRL +/7 ) glands, in contrast, developed an extensive ductal system decorated with ®ne branches and alveolar buds (Horseman et al., 1997) . We con®rmed that qualitative observation here, and extended it by studying aged mice and hormonal rescue of the phenotype, and by quantifying branch densities in treatment groups. We observed that the poor epithelial development of PRL 7/7 mice was perpetuated through old age. Therefore, the mammary gland development in PRL 7/7 mice was arrested at a stage of simple ductal growth, not merely delayed. Chronic PRL exposure from pituitary grafts induced growth of a complex epithelial network of subordinate branches and alveolar buds, which appeared to be normal on both a qualitative and quantitative basis. Chronic treatment with progesterone alone induced only a partial rescue of the defective mammary gland development in PRL 7/7 mice. PRL 7/7 mice exhibited irregular cycles, as evidenced by vaginal cytology and sexual receptivity; and no PRL 7/7 females produced litters after mating (Horseman et al., 1997). To further assess the competence of PRL 7/7 mammary glands to dierentiate, it was of interest for us to establish viable pregnancies in these mice. The hormonal changes of pregnancy and subsequent lactation initiate a series of reversible dierentiative changes in the mammary gland, which are distinguishable from the organogenesis of puberty. Since PRL is luteotrophic in mice (Nicoll, 1974) , failure to implant normally after mating suggested a possible shortage of luteal progesterone. By supplementing PRL 7/7 with a pellet of progesterone, and pairing them with a fertile male, we were successful in establishing pregnancies in two out of four progester- mice. In PRL 7/7 mice which became pregnant using this paradigm, mammary glands took on the appearance expected during gestation. Lobuloalveolar dierentiation and ductal branching were comparable to the morphological changes seen in normal pregnant mice. These observations make it clear that placental lactogens, in the presence of progesterone (and other ovarian steroids), are capable of supporting mammary gland development in pregnancy in the mouse, even in the absence of pituitary or extrapituitary PRL synthesis.
Pubertal mammary gland organogenesis is an irreversible set of developmental changes that are under the control of both gonadal and pituitary hormones (Forsyth, 1982) . As ductal and epithelial structures proliferate, growth is initially predominant at the terminal end buds. Glandular structures eventually extend throughout the mammary fat pad. These may be more or less extensive, depending on the strain of mouse and its hormonal condition. Under the in¯uences of pregnancy, lobuloalveolar growth becomes more extensive than in a nulliparous animal, however, the proliferative and secretory changes associated with pregnancy and lactation are readily reversed after weaning, whereas the changes that occur during puberty are retained throughout adulthood.
In mice that were prepubertally ovariectomized estradiol alone led to the exaggeration of terminal end bud activity, but not to extensive penetration of the epithelium into the fat pad, or arborization of the ductal system. It is believed that estrogen can aect mammary gland development growth by virtue of its ability to induce progesterone receptors (Haslam, 1988; Wang et al., 1990) and PRL receptors (Ormandy et al., 1992) . The addition of progesterone and PRL resulted in extensive penetration of the mammary fat pad, along with dichotomous and subordinate branching as would be expected during normal pubertal development. Alveolar budding was seen only in the most mature portion of mammary tissue that was treated with all three hormones (Figure 2d ).
Stat proteins have been implicated in the mediation of PRL-induced mammary development (Darnell et al., 1994; Horseman and Yu-Lee, 1994; Liu et al., 1997; Wakao et al., 1994) . When PRL binds to its receptor, it triggers a cascade of events, including activation of ). (a) The ages (days) on which tumors were ®rst detected, or when tumors reach 1 cm diameter were recorded for each mouse, and the mean (+s.e.m.) is graphed for PRL +/7 (Control) and PRL 7/7 (PRLKO) mice. (b) Mammary adenocarcinoma from PRL +/7 (left panel) and PRL 7/7 (right panel) mice. Tumors from mice of both genotypes were indistinguishable on morphological grounds. Examples are presented here to illustrate that both backgrounds yielded tumors that were highly transformed, invasive carcinomas. Mammary glands were taken at an early stage of tumor growth (maximum diameter 1 mm), formalin-®xed, paran-embedded and sectioned at 5 mm. Sections were stained with hematoxylin/eosin, photographed and reproduced at a magni®cation of 5006. Examples of metaplastic transformation (white arrow, left panel) and invasion into surrounding stroma (black arrow, right panel) are identi®ed Jak2 protein-tyrosine kinase, and phosphorylation of various substrates including Stat proteins (Bole-Feysot et al., 1998) . According to the current understanding of the Stat activation, tyrosine phosphorylation of Stat proteins leads to dimerization through SH2-domain interactions. Activated Stat translocates to the nucleus and binds to DNA, thereby increasing speci®c mRNA synthesis. Tyrosine phosphorylation of Stat5, in particular, has been implicated in mammary growth and development Wakao et al., 1994) . Gene disruption of Stat5a results in a phenotype of lactational failure, which may be partially compensated by Stat5b Teglund et al., 1998; Udy et al., 1997) . To test the integrity of the PRL signal transduction in the mammary gland we compared Stat activation in PRL 7/7 and PRL +/7 mice by assaying DNA-binding and tyrosine phosphorylation.
Binding to the b-casein gene PRL-response element was equivalently activated by PRL within 30 min in both normal or PRL 7/7 mice. All of the PRLresponsive binding activity was supershifted by antibodies speci®c to Stat5a, implying that Stat5a is the major PRE-binding protein in PRL-treated mammary gland. Stat5 tyrosine phosphorylation was induced similarly in PRL 7/7 and PRL +/7 mammary glands. PRL has long been known to promote the growth of chemically-induced tumors in mice [reviewed in (Welsch and Nagasawa, 1977) ]. Transplanted pituitaries, which secrete high levels of PRL, enhanced tumorigenesis induced by N-methyl-N-nitrosourea (MNU) or 7,12-dimethylbenzanthracene (DMBA). PRL may have multiple activities that enhance mammary gland tumorigenesis. MNU-induced tumorigenesis was exaggerated if PRL was high at the time of carcinogen treatment (Swanson et al., 1994) , implying that PRL synergizes with carcinogen during initiation of tumors. PRL-induced proliferation may, therefore, increase the likelihood that oncogenic mutations become ®xed in the genomes of aected cells during the initial stages of chemically-induced tumorigenesis. Whether PRL can alter the growth of tumors independent of an action during initiation has been less clear. No previous studies have asked whether PRL de®ciency aects the growth of tumors initated by targeted expression of a dominant oncogene in the mammary gland.
We chose to study breast tumorigenesis in MMTVPyVT transgenic mice in which breast tumors occur in 100% of mice bearing the transgene. Male, as well as female PyVT mice develop breast tumors, although they occur later in life and grow more slowly than those in females (Guy et al., 1992) . The mechanism of PyVT-induced tumorigenesis is incompletely known, but clearly involves the activation of multiple intracellular tyrosine kinase signaling pathways (DiMaio et al., 1998; Garcia et al., 1997; Summers et al., 1998) . MMTV-PyVT mice, unlike strains bearing oncogenes driven by lactation-dependent promoters such as that for whey acidic protein (Bayna and Rosen, 1990) , do not require pregnancy to develop tumors. Therefore, it was possible to make valid comparisons between tumor growth in nulliparous PRL 7/7 mice and normal littermates. Our expectation when we began this experiment was that the tumorigenesis driven by the MMTV-PyVT transgene would bypass any anticipated PRL-dependent mechanisms, and that tumor growth would not be measurably dierent in the PRL-de®cient females. We were somewhat surprised to observe that tumors appeared later and grew about 30% more slowly in the PRL-de®cient mice. We assume that the initiation events and genetic anomalies that underlie PyVT-induced tumors occur independently of PRL. Subsequent proliferation and cell death control mechanisms would seem to be the most likely explanations for the PRL-dependent increment in tumor growth. PRL may act as a direct mitogen for breast cancer cells (Das and Vonderhaar, 1997) ; and, although the degree of PRL-induced breast cell proliferation has been shown to be modest in most studies, a cumulative eect could be large in rapidly growing tumors. An anti-apoptotic action of PRL in the tumors might also explain the increase in their overall growth rate. Whether PRL aects apoptosis in mammary gland cells is not known, but PRL is a potent anti-apoptotic agent in Nb2 lymphoma cells (Krumenacker et al., 1998) . Stat5a, which is activated in response to PRL, is antiapoptotic in mouse mammary glands (Li et al., 1997) . PRL might also support more rapid tumor growth in PyVT mice by enhancing tumor-associated angiogenesis. Experiments that address whether any of these possible mechanisms is causally associated with PRL-induced tumor growth will provide insights into PRL-regulated pathways that may be responsible for not only abnormal growth in tumors, but also in normal target tissues.
There are two, equally valid, perspectives from which one can view our data on tumor growth in PRL 7/7 mice. On the one hand, PRL de®ciency caused a rather large, and consistent, 30% decrease in tumor growth in a model which produces very aggressive, fast growing, metastatic breast cancers. On the other hand, the PRL 7/7 mice have an absolute de®ciency of both central and local sources of PRL biosynthesis. Because tumor growth in this model is only modestly sensitive to absolute PRL de®ciency, PyVT-induced breast tumors are ultimately no less injurious in PRL 7/7 mice.
Summary
These studies provide a basis for a better understanding of PRL signaling in normal mammary gland development, and PRL signaling in mammary tumor growth. Mammary gland development and Stat5a responded equivalently in adult PRL-de®cient and normal mice. Breast tumor growth was signi®cantly decreased in PRL-de®cient mice, suggesting possible involvement of anti-apoptotic or angiogenic actions of PRL in breast tumor promotion. Studies in mice with isolated de®ciency of PRL can substantially clarify PRL mechanisms in mammary gland development and breast cancer.
Materials and methods
Female mice with a targeted disruption of the prolactin gene (PRL 7/7
) were described previously (Horseman et al., 1997) . The mice were subjected to the treatments outliend below to assess hormonal eects on mammary gland development. Ovine PRL (NIH oPRL-20, 35 IU/mg) was dissolved in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl (TBS) and administered at a dose of 1 mg/g body weight by twice daily injections early and late in the daytime; estradiol benzoate or medroxyprogesterone acetate (Sigma Chemical Co., St. Louis, MO, USA) were dissolved in peanut oil for the injections. Donor pituitaries were harvested from littermate heterozygous females, and inserted under the kidney capsule of recipients within minutes of removal. Viability of grafts was con®rmed by immunostaining the graft sites with antimouse PRL. Mice were maintained in speci®c pathogen-free barrier facilities and their husbandry, surgeries and other procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee.
Mammary gland development
Mammary glands were from the following treatment groups, for which the results are shown in Figures 1 and 2: (1 mice implanted with a progesterone pellet as in (4) and mated with a proven stud male on the night after the implant. Killed on day 19 of pregnancy; (6) Intact, aged (17 months old) PRL 7/ 7 mouse; (7) Mice were bilaterally ovariectomized (OVX) 4 ± 5 days after weaning. OVX mice were allowed to recover at least 10 days before the injections were begun. Treated with estradiol benzoate (EB), 1 mg in 1.0 ml oil on days 1, 4, 7 and 10; (8) Ovariectomized mice treated with EB (days 1, 4, 7 and 10), plus medroxyprogesterone acetate (days 2, 5, 8 and 11; 12.5 mg in 0.1 ml oil), plus PRL (1 mg/g body weight in TBS, days 2 ± 11).
The right abdominal mammary glands from each animal was excised and processed for whole mount histology as previously described (Horseman et al., 1997) . Video images of stained glands were digitized and used to determine branch densities in each gland. The images were displayed with an overlying grid such that each box of the grid pattern represented a 1 mm 2 area of the gland, and the branch points within the gridded areas were counted. A total of 12 boxes were selected using a random number table and the counts of the 12 boxes was averaged. Statistical treatment of the branch density data was by analysis of variance for treatment eects.
Stat5 phosphorylation and DNA binding
Intact PRL 7/7 and PRL +/7 mice were given a single injection of PRL (1 mg/g body weight) or vehicle (TBS). Mammary tissues were harvested 30 min after injection and processed for biochemical analyses. Tissues were washed with PBS containing 1 mM sodium orthovanadate and frozen at 7808C. High salt extracts were prepared by freeze-thaw lysis (Gao et al., 1996) . In Stat5 tyrosine phosphorylation studies, equal masses of protein from each gland were incubated with anti-Stat5 (C17, Santa Cruz Biotechnologies, CA, USA) and the complexes were precipitated with protein A-sepharose. The pellets were resuspended in loading buer and subjected to SDS ± PAGE in 4 ± 15% gradient gels. Gels were blotted on nitrocellulose membranes, and immunodetection was performed with the RC20H antibody (Transduction Laboratories, Lexington, KY, USA). Electrophoretic mobility shift (EMSA) analysis was done by incubation of protein extracts with radiolabeled oligonucleotide equivalent to the rat bcasein PRL response element (PRE) sequence as described previously (Gao et al., 1995; Sidis and Horseman, 1994) .
Antibodies and Western blotting
Anity puri®ed antibodies to Stat5 and Stat1 were purchased from Santa Cruz Biotechnologies (CA, USA). Immunoprecipitation and detection with horseradish peroxidase-conjugated secondary antibody were performed on extracts of whole abdominal mammary glands according to the protocols recommended by the supplier of the primary antibodies. Chemiluminescence detection was performed using the ECL Western blotting detection system (Amersham Life Science, Buckinghamshire, UK). Quanti®cation of the immunostained products was done by scanning the ®lm images and determining the integrated optical density of bands with NIH IMAGE. The measurements were compared by analysis of variance as above.
